Patent Number: 8,822,455

Title: Fused aminodihydrothiazine derivatives

Abstract: The present invention relates to a fused aminodihydrothiazine derivative of formula (I): ##STR00001## wherein R is hydrogen or C.sub.1-6alkyl, optionally substituted by one to five halogen atoms; n is 0, 1, 2 or 3; Ar is phenyl or a 5- or 6-membered heteroaromatic group containing 1, 2 or 3 N atoms, which Ar is optionally substituted by one to three substituents selected from hal, hydroxyl, --CN, C.sub.1-6alkyl, C.sub.2-3alkenyl, C.sub.2-3alkynyl, C.sub.1-6alkoxy, C.sub.3-6cycloalkoxy and pyrazine, where C.sub.1-6alkyl and C.sub.1-6alkoxy are optionally substituted by one to three halogen atoms; and pharmaceutically acceptable salts thereof; which compound has an A.beta. production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A.beta. and typified by Alzheimer-type dementia.

Inventors: Dimopoulos; Paschalis (Hatfield Hertfordshire, GB), Hall; Adrian (Hatfield Hertfordshire, GB), Kita; Yoichi (Tsukuba, JP), Madin; Andrew (Hatfield Hertfordshire, GB), Shuker; Nicola Louise (Hatfield Hertfordshire, GB)

Assignee: Eisai R&D Management Co., Ltd.

International Classification: C07D 513/14 (20060101); A61K 31/542 (20060101)

Expiration Date: 9/02/12018